Is Bausch + Lomb Corp (BLCO) overvalued? · rev $4.79B
Bausch + Lomb Corp (BLCO) is a medical instruments & supplies company listed on NYSE.
This page asks whether Bausch + Lomb Corp (BLCO) looks expensive on cached numbers — not a short thesis.
Latest reported BLCO revenue for 2024-12-31 was $4.79B. Net income was -$305.0M. Revenue was up 15.6% from 2023-12-31 to 2024-12-31. BLCO currently screens at market cap $5.38B.
BLCO currently screens at market cap $5.38B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BLCO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BLCO stock page for the full model, not this heading.
Not investment advice.